Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study

被引：0
|
作者：
Park, Wungki
O'Reilly, Eileen Mary
Furuse, Junji
Li, Chung-Pin
Oh, Do-Youn
Garcia-Carbonero, Rocio
Roth, Gael
Lee, Ho-Jin
Kunieda, Futoshi
机构：
[1] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Kyorin Univ, Dept Med Oncol, Fac Med, Mitaka, Tokyo, Japan
[3] Taipei Vet Gen Hosp, Div Gastroenterol, Dept Med, Taipei, Taiwan
[4] Seoul Natl Univ, Seoul Natl Univ Hosp, Canc Res Inst, Dept Internal Med,Coll Med, Seoul, South Korea
[5] 12 Octubre Univ Hosp, Madrid, Spain
[6] Univ Hosp Grenoble, Hepato Gastroenterol Dept, Grenoble, France
[7] Astellas Pharma Inc, Northbrook, IL USA
[8] Astellas Pharma Inc, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4186
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Zolbetuximab with gemcitabine plus nab-paclitaxel (GN) in first-line treatment of Claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase II, open-label, randomized study
    Park, W.
    O'Reilly, E. M.
    Li, C-P.
    Oh, D-Y.
    Garcia-Carbonero, R.
    Roth, G.
    Nakajima, T.
    Moran, D.
    Yang, J.
    Li, R.
    Kunieda, F.
    ANNALS OF ONCOLOGY, 2024, 35 : S934 - S934
  • [2] Phase II, open-label, randomized study of first-line zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in Claudin 18.2-positive metastatic pancreatic cancer (mPC).
    Park, Wungki
    O'Reilly, Eileen Mary
    Furuse, Junji
    Kunieda, Futoshi
    Jie, Fei
    Kindler, Hedy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study.
    Park, Wungki
    O'Reilly, Eileen Mary
    Furuse, Junji
    Li, Chung-Pin
    Oh, Do-Youn
    Garcia-Carbonero, Rocio
    Roth, Gael
    Lee, Ho-Jin
    Bhattacharya, Pranob P.
    Moran, Diarmuid Martin
    Yang, Jianning
    Kunieda, Futoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS782 - TPS782
  • [4] A multi-center, open-label, randomized controlled trial of nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine for first-line treatment of advanced pancreatic cancer (PC)
    Jin, M.
    Liu, H.
    Lin, Z.
    Xue, J.
    Liu, J.
    Bao, L.
    Luo, Z.
    Yu, X.
    Li, S.
    Hu, J.
    Zhang, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S311 - S311
  • [5] Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial
    Dorman, Klara
    Boeck, Stefan
    Caca, Karel
    Reichert, Maximilian
    Ettrich, Thomas J.
    Oettle, Helmut
    Waidmann, Oliver
    Modest, Dominik P.
    Mueller, Lothar
    Michl, Patrick
    Kanzler, Stephan
    Pink, Daniel
    Reinacher-Schick, Anke
    Geissler, Michael
    Pelz, Henning
    Kunzmann, Volker
    Held, Swantje
    Schichtl, Thomas
    Heinemann, Volker
    Kullmann, Frank
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (10): : 935 - 943
  • [6] FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer
    Ay, Seval
    Atci, Muhammed Mustafa
    Arikan, Rukiye
    Dulgar, Ozgecan
    Ozyukseler, Deniz Tataroglu
    Paksoy, Nail
    Dogan, Izzet
    Oztosun, Bugra
    Tastekin, Didem
    Oven, Basak Bala
    Gumus, Mahmut
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (07) : 465 - 471
  • [7] A phase 1b (open-label)/phase 2 (randomized, double-blinded) study evaluating nab-paclitaxel and gemcitabine with or without olaratumab in first-line treatment of metastatic pancreatic cancer.
    Bendell, Johanna C.
    Pelzer, Uwe
    Womack, Mark S.
    Borazanci, Erkut Hasan
    Bahary, Nathan
    Garrido-Laguna, Ignacio
    Maur, Michela
    Prater, Tyler
    Levy, Donna Elise
    Cronier, Damien
    Ramage, Sam
    Macarulla, Teresa
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [8] Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer
    Wainberg, Zev A.
    Hochster, Howard S.
    Kim, Edward J.
    George, Ben
    Kaylan, Aparna
    Chiorean, E. Gabriela
    Waterhouse, David M.
    Guiterrez, Martin
    Parikh, Aparna
    Jain, Rishi
    Carrizosa, Daniel Ricardo
    Soliman, Hatem H.
    Lila, Thomas
    Reiss, David J.
    Pierce, Daniel W.
    Bhore, Rafia
    Banerjee, Sibabrata
    Lyons, Larry
    Louis, Chrystal U.
    Ong, Teng Jin
    O'Dwyer, Peter J.
    CLINICAL CANCER RESEARCH, 2020, 26 (18) : 4814 - 4822
  • [9] VIRAGE: A phase IIb, open-label, randomized study of nab-paclitaxel and gemcitabine plus/minus VCN-01 in patients with metastatic pancreatic cancer
    Garcia-Carbonero, Rocio
    Cid, Roberto Pazo
    Macarulla, Teresa
    Nguyen, Alana
    Kim, Edward
    Laquente, Berta
    Seery, Tara Elisabeth
    Cazorla, Mireya
    Guillen-Ponce, Carmen
    De Castro, Eva Martinez
    Anton-Pascual, Beatriz
    Martin, Andres J. Munoz
    Lobo, Miriam
    Garrido-Laguna, Ignacio
    Le, Charles
    Kaleko, Michael
    Shallcross, Mary Ann
    Blasco, Carmen
    Cascallo, Manel
    Hidalgo, Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study
    Lei Yang
    Jing Su
    Wenbo Wang
    Fuxiang Zhou
    World Journal of Surgical Oncology, 21
12345